

NCTN Breast Cancer Trials Portfolio (Open as of 4/15/2026)

Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and study information.

Neoadjuvant	Post-Neoadjuvant	Adjuvant	Metastatic
<div data-bbox="142 284 451 479" style="background-color: #c8e6c9; padding: 5px; margin-bottom: 10px;"> <p>S2212 (SCARLET) TNBC T2-4/N0/M0, or T1-3/N1-2/M0</p> </div> <div data-bbox="142 527 451 673" style="background-color: #e1bee7; padding: 5px;"> <p>S2206 HR+/HER2- Stage II or III</p> </div>	<div data-bbox="550 284 955 503" style="background-color: #c8e6c9; padding: 5px; margin-bottom: 10px;"> <p>A012103 (OptimICE-PCR) TNBC Early-Stage, pCR post pre-op chemo + pembrolizumab</p> </div> <div data-bbox="550 544 955 763" style="background-color: #ffe0b2; padding: 5px;"> <p>A012303 (ShortStop-HER2) HER2+ Early-Stage, pCR post pre-op chemo + HER2 blockade</p> </div>	<div data-bbox="1050 284 1455 430" style="background-color: #e1bee7; padding: 5px; margin-bottom: 10px;"> <p>CCTG MA.39 HR+/HER2- Low risk; Node positive</p> </div> <div data-bbox="1050 479 1455 690" style="background-color: #e1bee7; padding: 5px; margin-bottom: 10px;"> <p>NRG-BR009 (OFSET) HR+/HER2- pT1-3/N0-1/M0, Oncotype Recurrence Score ≤ 25, Premenopausal patients</p> </div> <div data-bbox="1050 738 1455 933" style="background-color: #e1bee7; padding: 5px;"> <p>A012301 (LoTam) HR+/HER2- Early-stage, Low molecular risk, Resected tumor ≤3cm and N0, Postmenopausal pts</p> </div>	<div data-bbox="1575 284 1953 406" style="background-color: #fce4ec; padding: 5px; margin-bottom: 10px;"> <p>EAY191 (ComboMATCH)</p> </div> <div style="text-align: center; margin-bottom: 5px;">↓</div> <div data-bbox="1575 479 1974 625" style="background-color: #fce4ec; padding: 5px;"> <p>Sub-study: EAY191-E5 (KRAS G12C mutation)</p> </div>

Legend by Subtype Status

Green = TNBC

Orange = HER2+ (Any HR status)

Purple = HR+ and HER2-

Pink = Cross-disease trial

NCTN Breast Cancer Trials (Open as of 4/15/2026)

Protocol Number	Phase	Protocol Title
A012103	III	OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A012301	III	LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
A012303	III	ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade
CCTG MA.39	III	Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
NRG-BR009	III	A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score \leq 25 (OFSET)
S2206	III	Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
S2212	III	Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
EAY191	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)
EAY191-E5	II	A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial

This portfolio shows NCTN trials. For information about NCORP trials, please see: <https://ncorp.cancer.gov/find-a-study/>